ArticleMolecular pharmaceutics2019
Development and Evaluation of an
Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Optimization of next-generation CXCR4 ligands for radiotheranostic applications.Frontiers in pharmacology · 2026Review
- Theranostic applications of CXCR4-targeted imaging ligands in lymphoma: integrating diagnosis and precision therapy.American journal of nuclear medicine and molecular imaging · 2026Review
- Targeting the chemokine receptor CXCR4 for cancer therapies.Biomarker research · 2025Review
- PET imaging of CXCR4 expression using [Theranostics · 2024Article
- Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.Korean journal of radiology · 2023Review
- CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.Molecules (Basel, Switzerland) · 2023Review
- Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.European journal of nuclear medicine and molecular imaging · 2022Review
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.Pharmaceutics · 2022Review
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- PET Imaging Radiotracers of Chemokine Receptors.Molecules (Basel, Switzerland) · 2021Review
- Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.PloS one · 2021Article
- A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.Bioorganic & medicinal chemistry · 2020Article
- C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.Scientific reports · 2019Article
- Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
In humans, C-X-C chemokine receptor type 4 (CXCR4) is a protein that is encoded by the CXCR4 gene and binds the ligand CXCL12 (also known as SDF-1). The CXCR4-CXCL12 interaction in cancer elicits biological activities that result in tumor progression and has accordingly been the subject of significant investigation for detection and treatment of the disease. Peptidic antagonists have been labeled with a variety of radioisotopes for the detection of CXCR4, but the methodology utilizing small molecules has predominantly used radiometals. We report here the development of a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.